从1999年到2019年,极端软组织肉瘤的5年生存率逐步改善
Ryley K Zastrow1, Mohyeddine El Sayed2, Christa L LiBrizzi1
1Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA.
Sarcoma
|February 27, 2024
概括
极端软组织肉瘤 (ESTS) 的存活率在过去二十年中显著改善. 最近的趋势显示了更好的结果,可能是由于早期检测和先进的治疗这种罕见的癌症.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 癌症研究 癌症研究
背景情况:
- 极端软组织肉瘤 (ESTS) 是一种罕见且多样化的癌症群体.
- 虽然生存率在历史上有所改善,但最近的趋势需要更新分析.
- 本研究调查了ESTS的临床特征和生存趋势,从1999年到2019年.
研究的目的:
- 更新对ESTS临床特征的理解.
- 分析ESTS的5年生存率的最新趋势.
- 确定影响ESTS患者生存的预后因素.
主要方法:
- 使用SEER数据库 (1999-2019) 进行的回顾性队列研究.
- 包括5654名15岁以上的初级ESTS患者.
- 卡普兰-梅尔和考克斯回归分析在人口统计,临床和生存数据上进行.
主要成果:
- ESTS通常出现在下肢,高等级,大尺寸,没有转移.
- 在老年患者和没有转移的诊断患者中观察到显著增加.
- 五年生存率从47% (1999-2005) 提高到78% (2013-2019),死亡率下降.
结论:
- 在20年的研究期间,ESTS的五年生存率逐渐提高.
- 在老年患者中增加局部疾病的诊断可能有助于改善存活率.
- 早期检测和更有效的治疗是这些积极趋势的潜在驱动力.
相关概念视频
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


